A major real-world study published in early 2026 led by researchers at Johns Hopkins Bloomberg School of Public Health and analysing electronic health records from approximately 175,000 people with T1D in the US found that those taking GLP-1 drugs had a roughly 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease, without any increase in hospitalisation for DKA or severe hypoglycemia
Appetite regulation, cravings, energy balance, glucose control, and metabolic resilience depend on an interconnected biological network involving: gut microbiome composition dietary fiber fermentation short-chain fatty acid (SCFA) production gut barrier stability circadian rhythm signaling stress and cortisol biology metabolic inflammation Modern research shows that when this system is disrupted, GLP-1 signaling weakens , whether GLP-1 is stimulated naturally or pharmacologically
The effect of short-term dietary supplementation with glucose on gastric emptying of glucose and fructose and oral glucose tolerance in normal subjects
Documentation you need For international travel with GLP-1 medications, carry all of the following: Original prescription label on the medication Printed prescription from your prescribing provider A travel letter from your doctor stating the medication name, dose, and medical necessity Your doctor contact information in case customs needs verification Some countries require that medications be in their original pharmacy packaging
Semaglutide GLP-1 effectiveness in inducing weight loss has been observed, making it a popular choice for many of our patients
